Trevi Therapeutics, Inc.
TRVI
$14.76
-$0.12-0.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.97M | 4.03M | 3.83M | 4.33M | 3.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.91M | 10.22M | 13.92M | 13.72M | 11.47M |
| Operating Income | -14.91M | -10.22M | -13.92M | -13.72M | -11.47M |
| Income Before Tax | -13.21M | -8.33M | -11.82M | -12.32M | -10.35M |
| Income Tax Expenses | -20.00K | -16.00K | -15.00K | -21.00K | -11.00K |
| Earnings from Continuing Operations | -13.19M | -8.32M | -11.80M | -12.30M | -10.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.19M | -8.32M | -11.80M | -12.30M | -10.34M |
| EBIT | -14.91M | -10.22M | -13.92M | -13.72M | -11.47M |
| EBITDA | -14.88M | -10.19M | -13.88M | -13.68M | -11.43M |
| EPS Basic | -0.09 | -0.06 | -0.08 | -0.09 | -0.09 |
| Normalized Basic EPS | -0.06 | -0.04 | -0.05 | -0.06 | -0.06 |
| EPS Diluted | -0.09 | -0.06 | -0.08 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.06 | -0.04 | -0.05 | -0.06 | -0.06 |
| Average Basic Shares Outstanding | 145.59M | 145.50M | 145.11M | 130.35M | 117.61M |
| Average Diluted Shares Outstanding | 145.59M | 145.50M | 145.11M | 130.35M | 117.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |